INTRODUCTION
Rheumatoid arthritis (RA) is a chronic illness of unknown etiology characterized by symmetric, erosive joint inflammation throughout the body 1) . Treatment involves nonsteroidal anti-inflammatory drugs, glucocorticoids, and disease-modifying antirheumatic drugs (DMARDs) 2) . The extent of joint erosion in early disease has resulted in the early initiation of DMARDs being a mainstay of the management of patients with RA [3] [4] [5] with methotrexate (MTX) being the gold standard. However, remission is uncommon with these treatments and the long-term outcomes can be poor, with many patients switching medication due to lack of efficacy or adverse effects. Consequently, a sequential treatment strategy involving DMARDs that varies with disease progression is a common intervention.
Recently, the introduction of new DMARDs such as leflunomide (LEF) and tumor necrosis factor (TNF) antagonists (infliximab, etanercept [ETN] , and adalimumab) has transformed the management of RA [6] [7] [8] [9] .In particular, TNF antagonists have emerged as important therapies for RA because of their ability to reduce the signs and symptoms of disease, slow the rate of radiographic progression, and improve functional capacity.
ETN was approved for use in Korea in 2003.
The potential greater efficacy of ETN is associated with a much higher drug cost, making this a natural candidate for costeffectiveness analysis, and several studies have provided evidence of its costeffectiveness in patients with active RA who were resistant to traditional DMARDs therapy 10, 11) .
Whilst clinical guidelines currently recommend the use of ETN as a step therapy after a nonresponse to traditional DMARDs 2) , in early and established RA the combined use of ETN and MTX (the most widely used DMARD) is known to be more effective than monotherapy with either MTX or ETN alone 9, 12) . Moreover, there have been several reports that the induction of remission with early use of ETN+MTX regimen significantly improves functional status and quality of life (QoL) [13] [14] [15] . These observations implicate for the optimal use of expensive biologic therapy, and hence another economic analysis is required for the new treatment strategy.
Therefore, in this study we compared the long-term cost-effectiveness of a sequential treatment strategy involving the early use of ETN with that for the conventional late use of ETN in Korean RA patients.
MATERIALS AND METHODS

Model Framework
The model compared two hypothetical treatment sequences based on the societal perspective. The first sequence was the Decision analysis and Markov cohort simulation were used based on a previously published model 10, 16) . Outcomes were quantified as the quality-adjusted life years (QALYs). The model focused on the progression of the Health Assessment Questionnaire (HAQ) disability score, which ranges from 0 (best function) to 3 (worse function). The 6-monthly trends in HAQ score over time were simulated for 1000 patients using Microsoft Excel, and the regression of HAQ/EuroQol (EQ-5D) utility yielded the gain in QALYs.
The model cycle was 6 months. After the first 6-month cycle, a patient could be either an initial responder and remain on treatment, or a nonresponder and be switched to the next treatment in the sequence. The mean HAQ improvement for responders was quantified using published data 10, 17) . 71 [9] 64 [18, 29] 24 [8, 9, 39] 46 [40] Withdrawals at each 6-month period (%) 6.5 [18] 3.4 [9] 10.4 [18, 29] 14.7 [8, 9, 39] 19.2 [40] Initial HAQ improvement from baseline
-0.45 [18 29] -0.22 [8, 9, 39] -0.4 [40] HAQ improvement of ACR20 responders at 6 months -1.11 [10, 17] -0.83 [10, 17] -0.58 [10, 17] -0.38 [10, 17] -0.57 [10, 17] 6-monthly HAQ progression of ACR20 responders 0.0051 [41] 0.0051 [41] 0.017 [41] 0.017 [41] 0.017 [41] 6-monthly HAQ progression of ACR20 nonresponders 0.065 [42] 0.065 [42] 0.065 [42] 0.065 [42] for the modeling were extracted, and a meta-analysis was performed.
Modeling the Long-term Response to Treatment
Since switching to the next treatment was triggered by a lack of response or withdrawal, American College of Rheumatology-20 (ACR20) data and the withdrawal rates that were extracted from the finally selected clinicalliterature were used as transition probabilities. Table 1 lists the initial improvements in HAQ scores for the ACR20 responders. In cases where only the mean HAQ changes for both ACR20 responders and nonresponders were published, the HAQ score for ACR20 responders were estimated based on the formula ofBrennan et al 10) .
Subsequent long-term withdrawal occurred due to failure of treatment effect or adverse events. In cases where the ongoing drug therapy was withdrawn,it was assumed that the HAQ score increased again to the level of the first HAQ improvement after the administration of the corresponding drug.
Since one of the clinical pathways was death, the probability of death was included.
Considering that the mortality risk is higher for patients diagnosed with RA than for a normal population, a relative risk (RR) for mortality of 1.32 was applied 19) , and adjusted to the mortality of a normal population cohort obtained from the data of the Korea National
Statistical Office.
The model assumed a slight long-term progression of disability over time even when patients were responding to treatment based on Brennan et al. 10) . Regarding the HAQ progression level of ACR20 responders per cycle, the estimated value of 0.0051 was used for ETN+MTX, whereas 0.017 was used for MTX and MTX+LEF treatments as the long-term response to therapy. For the ACR20 nonresponders, the 6-month HAQ progression level of all drug therapy groups was estimated to be 0.065.
Regarding the calculation of QALY from HAQ, we assumed that HAQ was linearly related to EuroQol (EQ-5D) in accordance with previous studies [20] [21] [22] . In our study, the HAQ score was converted into QALYs based on the formula of Brennan et al. 10) : utility change = 0.86-0.20(HAQ score change).
Costs of Treatment Strategies
The cost of RA treatment included drug and monitoring costs, and was calculated by multiplying the health insurance payment with the frequency of drug administration and the frequency of monitoring ( Table 1) . For the purpose of sensitivity analysis the costs of lost productivity were also calculated based on the severity of RA disease, which was categorized into six stages according to the HAQ score. The costs of lost productivity were estimated based on work capacity.
We applied the research results of Kobelt et al. 23) , who calculated work capacity according (Table 2) . Also, it was considered that participation in financial activity occurred up to an age of 65 years on average, with retirement thereafter. Thus, the indirect costs were included only up to the age of 65
Analyses
Both strategies were simulated for 1000 patients using Excel. Estimated population mean costs and QALYs were calculated, and the incremental cost-effectiveness ratio (ICER) was determined from the mean differences in costs and QALYs. According to Korean guidelines for pharmacoeconomic evaluation 25) , this article took societal QALYs, quality-adjusted life years; ICER, incremental cost-effectiveness ratio. .
RESULTS
Base case analysis
The direct costs were estimated to be thousand won (Table 3) . Although no definitive willingness-to-pay threshold has been established in Korea, it undoubtedly exceeds those in the UK (£20,000-£40,000/QALY) 27) and US ($50,000/ QALY) 28) . This implies that adopting a , but we could not include this triple therapy in the sequence of step therapies for MTX-resistant patients.
Sensitivity analyse
Our analysis is likely to be conservative because we did not consider the savings in indirect costs from the early use of ETN in the base case analysis. The indirect costs from disability associated with RA are substantial 31) , including an increasing unemployment rate with increasing disease duration 32, 33) , and decreased productivity 34) . Key words: cost-benefit analysis, arthritis, rheumatoid, quality-adjusted life years.
